Chase C. Leavitt
CIK 1777467 · See Remarks · last filed 2026-05-11
Chase C. Leavitt is a corporate insider who has filed 17 SEC Form 4 insider transactions across 3 companies since 2019. The most recent filing, for MOBI, was dated May 11, 2026. Across all open-market trades the lifetime net is +$88.8K, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $6.3K across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.3K
3
17
$88.8K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| MOBI | See Remarks | 3,000 | — | — | $45.0K | 1 | 2026-05-11 |
| Oncternal Therapeutics, Inc. (ONCT) Delisted | General Counsel/Secretary | 84,758 | $0.53 | $44.6K | $38.7K | 12 | 2024-02-15 |
| LCTX | General Counsel/Secretary | 5,000 | $1.27 | $6.3K | $5.1K | 3 | 2021-03-17 |
Recent Filings
17 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-11 | MOBI | Mixed | +3,000 | $45.0K | EDGAR |
| 2024-02-15 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2024-01-05 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Tax (F) | −11,838 | -$5.9K | EDGAR |
| 2023-10-04 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Mixed | — | $0 | EDGAR |
| 2023-07-05 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Tax (F) | −10,305 | -$3.7K | EDGAR |
| 2023-04-14 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Buy (P) | +25,000 | $7.2K | EDGAR |
| 2023-02-23 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-01-05 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Tax (F) | −6,091 | -$6.2K | EDGAR |
| 2022-08-01 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | +43,125 | $0 | EDGAR |
| 2022-01-31 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Buy (P) | +13,500 | $23.3K | EDGAR |